Pseudomonas aeruginosa

Pseudomonas aeruginosa
Name	Pseudomonas aeruginosa
Domain	Bacteria
Phylum	Pseudomonadota
Class	Gammaproteobacteria
Order	Pseudomonadales
Family	Pseudomonadaceae
Genus	Pseudomonas
Species	P. aeruginosa
Binomial	Pseudomonas aeruginosa
Binomial authority	(Migula) 1900

Pseudomonas aeruginosa. It is a common Gram-negative, rod-shaped bacterium known for its metabolic versatility and intrinsic resistance to many antimicrobial agents. This opportunistic pathogen is a leading cause of severe, often life-threatening infections in hospitalized patients, individuals with cystic fibrosis, and those with compromised immune systems. Its ability to form resilient biofilms and its extensive arsenal of virulence factors make it a formidable challenge in clinical and community settings.

Characteristics

This bacterium is characterized as a motile, obligate aerobe that can also grow anaerobically using nitrate as an alternative electron acceptor. It produces several identifiable pigments, including the blue-green pyocyanin and the fluorescent pyoverdine, which contribute to its classic appearance in culture. The organism exhibits remarkable metabolic diversity, capable of utilizing over one hundred organic compounds, allowing it to thrive in diverse environments from soil and water to hospital surfaces. Its relatively large genome, such as the sequenced strain PAO1, encodes numerous regulatory systems, including the quorum sensing circuits LasI/LasR and RhlI/RhlR, which control the expression of many virulence factors.

Pathogenesis

The pathogenesis is mediated by a complex array of cell-associated and secreted factors. Key adhesins like type IV pili and flagella facilitate attachment and colonization of host tissues. The bacterium secretes numerous destructive exotoxins, most notably exotoxin A, which inhibits protein synthesis in host cells, and the pore-forming exoenzyme S. It also produces several hydrolases, including elastase and alkaline protease, which cause tissue damage. A critical aspect of its virulence is the formation of protective biofilms, which are structured communities embedded in a polysaccharide matrix, enhancing resistance to phagocytosis and antibiotics. This process is tightly regulated by quorum sensing systems.

Infections

It is a predominant cause of healthcare-associated infections, particularly in intensive care units. It is a classic agent of ventilator-associated pneumonia and a common pathogen in burn wound infections and surgical site infections. In patients with cystic fibrosis, chronic colonization of the lungs leads to a persistent, destructive bronchitis that is a major cause of morbidity and mortality. Other serious infections include bacteremia, urinary tract infections (especially with prolonged catheterization), and keratitis associated with contact lens wear or ocular trauma. Infections of the external ear (otitis externa) can be severe, such as in malignant otitis externa in diabetic patients.

Treatment

Treatment is notoriously difficult due to both intrinsic and acquired resistance mechanisms. Intrinsic resistance stems from low outer membrane permeability, efflux pumps like the MexAB-OprM system, and inducible ampC β-lactamases. Therapeutic options often require combination therapy, typically involving an antipseudomonal β-lactam such as piperacillin-tazobactam, cefepime, or meropenem, paired with an aminoglycoside like tobramycin or a fluoroquinolone such as ciprofloxacin. The rise of multidrug-resistant and extensively drug-resistant strains, including some producing carbapenemases like VIM or NDM, has led to the renewed use of older agents like colistin and the development of novel combinations like ceftolozane-tazobactam and ceftazidime-avibactam.

Epidemiology

As a ubiquitous environmental bacterium, it is found in soil, water, and vegetation, and can colonize moist reservoirs in hospitals, such as sink drains, respirator tubing, and disinfectant solutions. It is a major cause of outbreaks in healthcare settings, particularly in neonatal ICUs and burn units. Certain clones, such as the Liverpool epidemic strain and Manchester epidemic strain, have been associated with chronic infection in cystic fibrosis populations across Europe and North America. Surveillance networks like the SENTRY Antimicrobial Surveillance Program and the CDC's National Healthcare Safety Network track its prevalence and resistance patterns.

Research

Ongoing research is multifaceted, focusing on novel therapeutic strategies to overcome resistance. This includes the development of new antibiotics, phage therapy using bacteriophages, and antivirulence therapy aimed at disrupting quorum sensing or biofilm formation. Significant effort is directed at vaccine development, with candidates targeting components like the type III secretion system or outer membrane proteins in clinical trials. The study of its extensive genome and regulons, including the role of small regulatory RNAs, continues to reveal new insights into its adaptability and pathogenicity. Research into chronic infection in cystic fibrosis models is crucial for understanding host-pathogen evolution.

Category:Pseudomonadaceae Category:Healthcare-associated infections Category:Antibiotic-resistant bacteria